Sepsis Clinical Trial
Official title:
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
This is a prospective, randomized Phase III trial of FLAC chemotherapy with GM-CSF versus
PIXY321 in advanced breast cancer. The primary endpoints of this study will be the duration
of thrombocytopenia and the time to recovery of platelets to 50,000/microliters. Other
clinical endpoints will include the depth and duration of leukopenia, neutropenia, and
anemia, the platelet and RBC transfusion requirements, and the number of documented
instances of sepsis and hospitalizations for fever and neutropenia.
Laboratory correlates will include the detailed evaluation of the effects on circulating
hematopoietic progenitor cells by GM-CSF and PIXY321 and the potential effects these agents
have on the bone marrow micro-environment.
After 5 cycles of FLAC with GM-CSF versus PIXY321, patients will be treated with 5 cycles of
96 hour infusional taxol. The goal of this part of the study will be to assess the toxicity
and feasibility of administering infusional taxol following dose-intensive FLAC
chemotherapy.
This is a prospective, randomized Phase III trial of FLAC chemotherapy with GM-CSF versus
PIXY321 in advanced breast cancer. The primary endpoints of this study will be the duration
of thrombocytopenia and the time to recovery of platelets to 50,000/microliters. Other
clinical endpoints will include the depth and duration of leukopenia, neutropenia, and
anemia, the platelet and RBC transfusion requirements, and the number of documented
instances of sepsis and hospitalizations for fever and neutropenia.
Laboratory correlates will include the detailed evaluation of the effects on circulating
hematopoietic progenitor cells by GM-CSF and PIXY321 and the potential effects these agents
have on the bone marrow micro-environment.
After 5 cycles of FLAC with GM-CSF versus PIXY321, patients will be treated with 5 cycles of
96 hour infusional taxol. The goal of this part of the study will be to assess the toxicity
and feasibility of administering infusional taxol following dose-intensive FLAC
chemotherapy.
;
Endpoint Classification: Efficacy Study, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
| Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
| Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
| Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
| Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
| Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
| Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
| Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
| Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
| Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
| Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
| Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
| Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
| Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
| Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
| Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
| Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
| Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
| Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
| Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |